$CVS
CVS HEALTH Corp

2020 Q4 Form 10-Q Financial Statement

#000006480320000041 Filed on November 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $69.55B $67.06B $64.81B
YoY Change 3.98% 3.47% 36.47%
Cost Of Revenue $42.45B $40.94B $40.44B
YoY Change 0.92% 1.24% 2.37%
Gross Profit $27.10B $26.12B $24.37B
YoY Change 9.18% 7.15% 205.12%
Gross Profit Margin 38.97% 38.95% 37.61%
Selling, General & Admin $9.295B $8.685B $8.550B
YoY Change 10.73% 1.58% 71.86%
% of Gross Profit 34.3% 33.26% 35.08%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $24.44B $8.471B $8.595B
YoY Change 13.53% -1.44% 72.76%
Operating Profit $2.662B $3.249B $2.928B
YoY Change -12.35% 10.96% 13.75%
Interest Expense -$678.0M $731.0M $747.0M
YoY Change -7.63% -2.14% 10.83%
% of Operating Profit -25.47% 22.5% 25.51%
Other Income/Expense, Net $53.00M $54.00M $31.00M
YoY Change 70.97% 74.19% -3200.0%
Pretax Income $1.225B $1.806B $2.133B
YoY Change -47.51% -15.33% 12.32%
Income Tax $241.0M $587.0M $604.0M
% Of Pretax Income 19.67% 32.5% 28.32%
Net Earnings $973.0M $1.224B $1.530B
YoY Change -44.3% -20.0% 10.07%
Net Earnings / Revenue 1.4% 1.83% 2.36%
Basic Earnings Per Share $0.93 $1.17
Diluted Earnings Per Share $740.5K $0.93 $1.17
COMMON SHARES
Basic Shares Outstanding 1.309B shares 1.310B shares 1.302B shares
Diluted Shares Outstanding 1.315B shares 1.305B shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.85B $12.09B $7.527B
YoY Change 34.73% 60.58% -81.95%
Cash & Equivalents $7.854B $9.256B $5.193B
Short-Term Investments $3.000B $2.831B $2.334B
Other Short-Term Assets $5.277B $5.830B $4.841B
YoY Change 3.21% 20.43% 663.56%
Inventory $18.50B $17.48B $16.03B
Prepaid Expenses
Receivables $21.74B $23.82B $19.79B
Other Receivables $2.198B $3.171B $2.007B
Total Short-Term Assets $56.37B $59.21B $48.19B
YoY Change 12.06% 22.88% -33.06%
LONG-TERM ASSETS
Property, Plant & Equipment $12.61B $12.35B $11.65B
YoY Change 4.67% 5.99% 11.82%
Goodwill $79.55B $79.58B $79.55B
YoY Change -0.25% 0.04%
Intangibles $31.14B $31.70B $33.66B
YoY Change -5.98% -5.82%
Long-Term Investments $20.81B $20.22B $17.34B
YoY Change 20.2% 16.57%
Other Assets $4.624B $4.569B $4.385B
YoY Change 0.52% 4.2% 154.35%
Total Long-Term Assets $174.3B $173.7B $171.9B
YoY Change 1.28% 1.02% 188.83%
TOTAL ASSETS
Total Short-Term Assets $56.37B $59.21B $48.19B
Total Long-Term Assets $174.3B $173.7B $171.9B
Total Assets $230.7B $232.9B $220.1B
YoY Change 3.72% 5.81% 67.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $34.87B $34.99B $29.56B
YoY Change 12.58% 18.4% 39.67%
Accrued Expenses $14.24B $14.33B $11.62B
YoY Change 17.39% 23.37% 88.56%
Deferred Revenue $71.00M $75.00M $72.00M
YoY Change -2.74% 4.17%
Short-Term Debt $0.00 $0.00 $1.070B
YoY Change -100.0%
Long-Term Debt Due $5.440B $5.443B $3.778B
YoY Change 43.88% 44.07% 76.62%
Total Short-Term Liabilities $62.02B $62.04B $52.54B
YoY Change 16.35% 18.08% 78.36%
LONG-TERM LIABILITIES
Long-Term Debt $59.21B $61.55B $64.21B
YoY Change -8.49% -4.13% 5.69%
Other Long-Term Liabilities $2.351B $2.520B $2.178B
YoY Change 8.74% 15.7% 34.03%
Total Long-Term Liabilities $2.351B $2.520B $66.38B
YoY Change -96.48% -96.2% 6.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $62.02B $62.04B $52.54B
Total Long-Term Liabilities $2.351B $2.520B $66.38B
Total Liabilities $161.0B $163.8B $157.2B
YoY Change 1.73% 4.2% 65.65%
SHAREHOLDERS EQUITY
Retained Earnings $49.64B $49.33B $44.02B
YoY Change 10.05% 12.07%
Common Stock $17.00M $17.00M $17.00M
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $28.18B $28.16B $28.21B
YoY Change -0.2% -0.15%
Treasury Stock Shares 423.0M shares 423.0M shares 424.0M shares
Shareholders Equity $69.39B $68.81B $62.61B
YoY Change
Total Liabilities & Shareholders Equity $230.7B $232.9B $220.1B
YoY Change 3.72% 5.81% 67.38%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income $973.0M $1.224B $1.530B
YoY Change -44.3% -20.0% 10.07%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $3.567B $1.874B $2.928B
YoY Change 35.42% -36.0% 166.91%
INVESTING ACTIVITIES
Capital Expenditures -$713.0M -$534.0M -$601.0M
YoY Change 25.75% -11.15% 11.3%
Acquisitions
YoY Change
Other Investing Activities -$521.0M -$836.0M -$228.0M
YoY Change 266.9% 266.67% 142.55%
Cash From Investing Activities -$1.234B -$1.370B -$829.0M
YoY Change 74.05% 65.26% 30.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.735B -6.117B -2.968B
YoY Change 159.38% 106.1% 10.21%
NET CHANGE
Cash From Operating Activities 3.567B 1.874B 2.928B
Cash From Investing Activities -1.234B -1.370B -829.0M
Cash From Financing Activities -3.735B -6.117B -2.968B
Net Change In Cash -1.402B -5.613B -869.0M
YoY Change -389.07% 545.91% -61.03%
FREE CASH FLOW
Cash From Operating Activities $3.567B $1.874B $2.928B
Capital Expenditures -$713.0M -$534.0M -$601.0M
Free Cash Flow $4.280B $2.408B $3.529B
YoY Change 33.71% -31.77% 115.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000064803
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2020Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2019Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201613Member
us-gaap Change In Accounting Principle Accounting Standards Update Transition Option Elected Extensible List
ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList
us-gaap:AccountingStandardsUpdate201615ProspectiveMember
dei Document Type
DocumentType
10-Q
dei Document Transition Report
DocumentTransitionReport
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Entity File Number
EntityFileNumber
001-01011
dei Entity Registrant Name
EntityRegistrantName
CVS HEALTH CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
05-0494040
dei Entity Address Address Line1
EntityAddressAddressLine1
One CVS Drive,
dei Entity Address City Or Town
EntityAddressCityOrTown
Woonsocket,
dei Entity Address State Or Province
EntityAddressStateOrProvince
RI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02895
dei City Area Code
CityAreaCode
(401)
dei Local Phone Number
LocalPhoneNumber
765-1500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
CVS
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1308913498 shares
CY2020Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
17182000000 USD
CY2019Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
15539000000 USD
us-gaap Premiums Earned Net
PremiumsEarnedNet
51749000000 USD
us-gaap Premiums Earned Net
PremiumsEarnedNet
47612000000 USD
CY2020Q3 us-gaap Net Investment Income
NetInvestmentIncome
204000000 USD
CY2019Q3 us-gaap Net Investment Income
NetInvestmentIncome
263000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
550000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
805000000 USD
CY2020Q3 us-gaap Revenues
Revenues
67056000000 USD
CY2019Q3 us-gaap Revenues
Revenues
64810000000 USD
us-gaap Revenues
Revenues
199152000000 USD
us-gaap Revenues
Revenues
189887000000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
40940000000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
40437000000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
121529000000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
116654000000 USD
CY2020Q3 us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
14396000000 USD
CY2019Q3 us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
12850000000 USD
us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
40534000000 USD
us-gaap Policyholder Benefits And Claims Incurred Health Care
PolicyholderBenefitsAndClaimsIncurredHealthCare
39396000000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
8471000000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
8595000000 USD
us-gaap Operating Expenses
OperatingExpenses
25702000000 USD
us-gaap Operating Expenses
OperatingExpenses
24887000000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
63807000000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
61882000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
187765000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
180937000000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3249000000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2928000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
11387000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
8950000000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
731000000 USD
CY2019Q3 us-gaap Interest Expense
InterestExpense
747000000 USD
us-gaap Interest Expense
InterestExpense
2229000000 USD
us-gaap Interest Expense
InterestExpense
2301000000 USD
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-766000000 USD
CY2019Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-79000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-766000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-79000000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
54000000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
153000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
93000000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1806000000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2133000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
8545000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
6663000000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
587000000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
604000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2328000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1776000000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
1219000000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
1529000000 USD
us-gaap Profit Loss
ProfitLoss
6217000000 USD
us-gaap Profit Loss
ProfitLoss
4887000000 USD
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5000000 USD
CY2019Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
1224000000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
1530000000 USD
us-gaap Net Income Loss
NetIncomeLoss
6206000000 USD
us-gaap Net Income Loss
NetIncomeLoss
4887000000 USD
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.93
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.76
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.93
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.75
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1310000000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1302000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1308000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1300000000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1315000000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1305000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1314000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1303000000 shares
CY2020Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
CY2019Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.50
CY2020Q3 us-gaap Profit Loss
ProfitLoss
1219000000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
1529000000 USD
us-gaap Profit Loss
ProfitLoss
6217000000 USD
us-gaap Profit Loss
ProfitLoss
4887000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
44000000 USD
CY2019Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
136000000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
257000000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
721000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
153000000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
157000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-3000000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-23000000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-15000000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-30000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
1000000 USD
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
42000000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
266000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
236000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
848000000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1261000000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1795000000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
6453000000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
5735000000 USD
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5000000 USD
CY2019Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1266000000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1796000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6442000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5735000000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9256000000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5683000000 USD
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
2831000000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
2373000000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23816000000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19617000000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
17478000000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
17516000000 USD
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
5830000000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5113000000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
59211000000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
50302000000 USD
CY2020Q3 us-gaap Long Term Investments
LongTermInvestments
20216000000 USD
CY2019Q4 us-gaap Long Term Investments
LongTermInvestments
17314000000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12349000000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12044000000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20484000000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20860000000 USD
CY2020Q3 us-gaap Goodwill
Goodwill
79579000000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
79749000000 USD
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
31697000000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
33121000000 USD
CY2020Q3 us-gaap Separate Account Assets
SeparateAccountAssets
4793000000 USD
CY2019Q4 us-gaap Separate Account Assets
SeparateAccountAssets
4459000000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4569000000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4600000000 USD
CY2020Q3 us-gaap Assets
Assets
232898000000 USD
CY2019Q4 us-gaap Assets
Assets
222449000000 USD
CY2020Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
11677000000 USD
CY2019Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
10492000000 USD
CY2020Q3 cvs Pharmacy Claimsand Discounts Payable Current
PharmacyClaimsandDiscountsPayableCurrent
15722000000 USD
CY2019Q4 cvs Pharmacy Claimsand Discounts Payable Current
PharmacyClaimsandDiscountsPayableCurrent
13601000000 USD
CY2020Q3 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
7593000000 USD
CY2019Q4 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Net
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
6879000000 USD
CY2020Q3 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
3964000000 USD
CY2019Q4 us-gaap Other Policyholder Funds
OtherPolicyholderFunds
2991000000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14329000000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12133000000 USD
CY2020Q3 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1527000000 USD
CY2019Q4 cvs Other Insurance Liabilities Current
OtherInsuranceLiabilitiesCurrent
1830000000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1789000000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1596000000 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
5443000000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
3781000000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
62044000000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53303000000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18489000000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18926000000 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
61552000000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
64699000000 USD
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7253000000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7294000000 USD
CY2020Q3 us-gaap Separate Accounts Liability
SeparateAccountsLiability
4793000000 USD
CY2019Q4 us-gaap Separate Accounts Liability
SeparateAccountsLiability
4459000000 USD
CY2020Q3 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
7135000000 USD
CY2019Q4 cvs Other Insurance Liabilities Noncurrent
OtherInsuranceLiabilitiesNoncurrent
7436000000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2520000000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2162000000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
163786000000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
158279000000 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3200000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1732000000 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1309000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1727000000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1302000000 shares
CY2020Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
46388000000 USD
CY2019Q4 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
45972000000 USD
CY2020Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
423000000 shares
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
425000000 shares
CY2020Q3 us-gaap Treasury Stock Value
TreasuryStockValue
28164000000 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
28235000000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
49328000000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
45108000000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1255000000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1019000000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
68807000000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
63864000000 USD
CY2020Q3 us-gaap Minority Interest
MinorityInterest
305000000 USD
CY2019Q4 us-gaap Minority Interest
MinorityInterest
306000000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
69112000000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
64170000000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
232898000000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
222449000000 USD
us-gaap Proceeds From Customers
ProceedsFromCustomers
195554000000 USD
us-gaap Proceeds From Customers
ProceedsFromCustomers
184519000000 USD
cvs Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies
PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies
116590000000 USD
cvs Paymentsfor Inventoryand Prescriptions Dispensedby Retail Network Pharmacies
PaymentsforInventoryandPrescriptionsDispensedbyRetailNetworkPharmacies
109958000000 USD
cvs Paymentsfor Insurance Benefits
PaymentsforInsuranceBenefits
40221000000 USD
cvs Paymentsfor Insurance Benefits
PaymentsforInsuranceBenefits
38812000000 USD
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
22185000000 USD
us-gaap Payments To Suppliers And Employees
PaymentsToSuppliersAndEmployees
21411000000 USD
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
622000000 USD
us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
756000000 USD
us-gaap Interest Paid Net
InterestPaidNet
2517000000 USD
us-gaap Interest Paid Net
InterestPaidNet
2675000000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2365000000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2205000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12298000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10214000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3790000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5616000000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6377000000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
6011000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1724000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1890000000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
828000000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
361000000 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
834000000 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-5000000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-16000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4300000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2630000000 USD
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
0 USD
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
350000000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
7919000000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
3458000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10493000000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
8350000000 USD
us-gaap Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
7000000 USD
us-gaap Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
25000000 USD
us-gaap Payments Of Dividends
PaymentsOfDividends
1980000000 USD
us-gaap Payments Of Dividends
PaymentsOfDividends
1952000000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
249000000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
183000000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
75000000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
85000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-33000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
11000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4420000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6410000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3578000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1174000000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4295000000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9532000000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5469000000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5954000000 USD
us-gaap Profit Loss
ProfitLoss
6217000000 USD
us-gaap Profit Loss
ProfitLoss
4887000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3302000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3275000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
288000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
355000000 USD
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
271000000 USD
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-205000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-766000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-79000000 USD
cvs Deferredincometaxesandothernoncashitems
Deferredincometaxesandothernoncashitems
-25000000 USD
cvs Deferredincometaxesandothernoncashitems
Deferredincometaxesandothernoncashitems
-38000000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3564000000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2312000000 USD
CY2020Q3 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-45000000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-413000000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
211000000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
374000000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3495000000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2330000000 USD
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
-474000000 USD
us-gaap Increase Decrease In Insurance Liabilities
IncreaseDecreaseInInsuranceLiabilities
535000000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2730000000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
859000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12298000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10214000000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
64170000000 USD
CY2020Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
2012000000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-332000000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
208000000 USD
CY2020Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2020Q1 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
53000000 USD
CY2020Q1 us-gaap Dividends Common Stock
DividendsCommonStock
657000000 USD
CY2020Q1 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
23000000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65474000000 USD
CY2020Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
2986000000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
526000000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
96000000 USD
CY2020Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
53000000 USD
CY2020Q2 us-gaap Dividends Common Stock
DividendsCommonStock
662000000 USD
CY2020Q2 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
-12000000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68355000000 USD
CY2020Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
1219000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
42000000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
112000000 USD
CY2020Q3 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
71000000 USD
CY2020Q3 us-gaap Dividends Common Stock
DividendsCommonStock
664000000 USD
CY2020Q3 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
-23000000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
69112000000 USD
CY2018Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2020Q3 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2020Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
58543000000 USD
CY2019Q1 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
1427000000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
331000000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
175000000 USD
CY2019Q1 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
7000000 USD
CY2019Q1 us-gaap Dividends Common Stock
DividendsCommonStock
651000000 USD
CY2019Q1 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
-4000000 USD
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60006000000 USD
CY2019Q2 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
1931000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
251000000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104000000 USD
CY2019Q2 cvs Treasury Stock Value Acquired Cost Method Net Of Espp Issuance
TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance
36000000 USD
CY2019Q2 us-gaap Dividends Common Stock
DividendsCommonStock
659000000 USD
CY2019Q2 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
2000000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
61599000000 USD
CY2019Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
1529000000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
266000000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
135000000 USD
CY2019Q3 cvs Espp Issuance Net Of Treasury Stock Value Acquired Cost Method
ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod
50000000 USD
CY2019Q3 us-gaap Dividends Common Stock
DividendsCommonStock
649000000 USD
CY2019Q3 cvs Noncontrollinginterest Other Period Increase Decrease
NoncontrollinginterestOtherPeriodIncreaseDecrease
3000000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
62933000000 USD
CY2019Q3 cvs Treasury Stock Shares Heldin Trust
TreasuryStockSharesHeldinTrust
1000000 shares
CY2019Q1 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2019Q3 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2018Q4 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2019Q2 cvs Treasury Stock Value Shares Held In Trust
TreasuryStockValueSharesHeldInTrust
29000000 USD
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
17000000 USD
CY2020Q3 cvs Numberof Pharmacy Plan Members
NumberofPharmacyPlanMembers
103000000 person
CY2020Q3 cvs Numberof Patients Servedper Year
NumberofPatientsServedperYear
1000000 patient
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 Segment
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform with the current year presentation.</span></div>
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9256000000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5683000000 USD
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
276000000 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
271000000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9532000000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5954000000 USD
cvs Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance
ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
269000000 USD
cvs Contractwith Customer Liability Redemptionand Breakage
ContractwithCustomerLiabilityRedemptionandBreakage
264000000 USD
CY2020Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7265000000 USD
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
6717000000 USD
CY2020Q3 cvs Vendorand Manufacturer Receivables
VendorandManufacturerReceivables
10528000000 USD
CY2019Q4 cvs Vendorand Manufacturer Receivables
VendorandManufacturerReceivables
7856000000 USD
CY2020Q3 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
2852000000 USD
CY2019Q4 us-gaap Premiums Receivable At Carrying Value
PremiumsReceivableAtCarryingValue
2663000000 USD
CY2020Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3171000000 USD
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2381000000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23816000000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19617000000 USD
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
363000000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
319000000 USD
CY2020Q3 us-gaap Net Investment Income
NetInvestmentIncome
204000000 USD
CY2020Q3 us-gaap Revenues
Revenues
67056000000 USD
CY2019Q3 us-gaap Net Investment Income
NetInvestmentIncome
263000000 USD
CY2019Q3 us-gaap Revenues
Revenues
64810000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
550000000 USD
us-gaap Revenues
Revenues
199152000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
805000000 USD
us-gaap Revenues
Revenues
189887000000 USD
CY2020Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7265000000 USD
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
6717000000 USD
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
75000000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
73000000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
73000000 USD
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
67000000 USD
cvs Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance
ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance
266000000 USD
cvs Contractwith Customer Liability Redemptionand Breakage
ContractwithCustomerLiabilityRedemptionandBreakage
264000000 USD
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
75000000 USD
us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
58000000 USD
CY2019Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
72000000 USD
CY2020Q3 cvs Health Insurer Fee
HealthInsurerFee
255000000 USD
cvs Health Insurer Fee
HealthInsurerFee
774000000 USD
cvs Non Tax Deductible Health Insurance Fee
NonTaxDeductibleHealthInsuranceFee
1000000000.0 USD
CY2020Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
5000000 USD
CY2019Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
14000000 USD
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
28000000 USD
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
26000000 USD
CY2020Q3 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
15000000 USD
CY2019Q3 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
20000000 USD
us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
72000000 USD
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
2831000000 USD
CY2020Q3 us-gaap Long Term Investments
LongTermInvestments
20216000000 USD
CY2020Q3 us-gaap Investments
Investments
23047000000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
2373000000 USD
CY2019Q4 us-gaap Long Term Investments
LongTermInvestments
17314000000 USD
CY2019Q4 us-gaap Investments
Investments
19687000000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
18863000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
4000000 USD
CY2020Q3 cvs Debt Securities Available For Sale Amortized Cost Net
DebtSecuritiesAvailableForSaleAmortizedCostNet
18859000000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1577000000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
38000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20398000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
15898000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2019Q4 cvs Debt Securities Available For Sale Amortized Cost Net
DebtSecuritiesAvailableForSaleAmortizedCostNet
15898000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1035000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
16922000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2020Q3 cvs Debt Securities Available For Sale Maturity Allocated And Single Maturity Date Within One Year Amortized Cost Net
DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateWithinOneYearAmortizedCostNet
1588000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1604000000 USD
CY2020Q3 cvs Debt Securities Available For Sale Maturity Allocated And Single Maturity Date After One Through Five Years Amortized Cost Net
DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAmortizedCostNet
6009000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6329000000 USD
CY2020Q3 cvs Debt Securities Available For Sale Maturity Allocated And Single Maturity Dateafter Five Through Ten Years Amortized Cost Net
DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateafterFiveThroughTenYearsAmortizedCostNet
3466000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
3774000000 USD
CY2020Q3 cvs Debt Securities Available For Sale Allocated And Single Maturity Date Maturity After10 Years Amortized Cost Net
DebtSecuritiesAvailableForSaleAllocatedAndSingleMaturityDateMaturityAfter10YearsAmortizedCostNet
3947000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
4704000000 USD
CY2020Q3 cvs Debt Securities Available For Sale Amortized Cost Net
DebtSecuritiesAvailableForSaleAmortizedCostNet
18859000000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
20398000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
1390 security
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
2177000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
35000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
97 security
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
82000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
3000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
1487 security
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
2259000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
38000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
522 security
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
982000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
6000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
200 security
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
187000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
5000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
722 security
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
1169000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
11000000 USD
CY2020Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear
36000000 USD
CY2020Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss
0 USD
CY2020Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears
624000000 USD
CY2020Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss
7000000 USD
CY2020Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears
504000000 USD
CY2020Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss
13000000 USD
CY2020Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears
296000000 USD
CY2020Q3 cvs Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss
8000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
2259000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
38000000 USD
CY2020Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
203000000 USD
CY2019Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
224000000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
550000000 USD
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
654000000 USD
CY2020Q3 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
8000000 USD
CY2019Q3 us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
10000000 USD
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
25000000 USD
us-gaap Investment Income Investment Expense
InvestmentIncomeInvestmentExpense
28000000 USD
CY2020Q3 cvs Investment Income Excluding Capital Gainsor Losses
InvestmentIncomeExcludingCapitalGainsorLosses
195000000 USD
CY2019Q3 cvs Investment Income Excluding Capital Gainsor Losses
InvestmentIncomeExcludingCapitalGainsorLosses
214000000 USD
cvs Investment Income Excluding Capital Gainsor Losses
InvestmentIncomeExcludingCapitalGainsorLosses
525000000 USD
cvs Investment Income Excluding Capital Gainsor Losses
InvestmentIncomeExcludingCapitalGainsorLosses
626000000 USD
CY2020Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
9000000 USD
CY2019Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
49000000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
25000000 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
179000000 USD
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
204000000 USD
CY2019Q3 us-gaap Investment Income Net
InvestmentIncomeNet
263000000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
550000000 USD
us-gaap Investment Income Net
InvestmentIncomeNet
805000000 USD
CY2020Q3 cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
1000000 USD
CY2020Q3 cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
2000000 USD
cvs Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
4000000 USD
cvs Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings
YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
44000000 USD
CY2019Q3 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
9000000 USD
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
22000000 USD
CY2020Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
905000000 USD
CY2019Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1325000000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2324000000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
4087000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
17000000 USD
CY2019Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
55000000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
60000000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
127000000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
3000000 USD
CY2019Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
9000000 USD
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
59000000 USD
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
13000000 USD
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in health care costs payable during the nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,147 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, beginning of the period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,143 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Components of incurred health care costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(511)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred health care costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,329 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,146 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Claims paid</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,063 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,285 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Premium deficiency reserve</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,585 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,010 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance recoverables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care costs payable, end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,593 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,014 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">_____________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Total incurred health care costs for the nine months ended September 30, 2020 and 2019 in the table above exclude (i) $1 million and $6 million, respectively, related to a premium deficiency reserve related to the Company’s Medicaid products, (ii) $31 million and $31 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the Company’s unaudited condensed consolidated balance sheets and (iii) $173 million and $213 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the Company’s unaudited condensed consolidated balance sheets.</span></div>
CY2020Q3 us-gaap Shortduration Insurance Contracts Incurred But Not Reported Ibnr Claims Liability Net
ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet
5800000000 USD
CY2020Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1036000000 USD
CY2019Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
808000000 USD
CY2020Q3 cvs Longterm Debt Gross And Lease Obligation
LongtermDebtGrossAndLeaseObligation
67721000000 USD
CY2019Q4 cvs Longterm Debt Gross And Lease Obligation
LongtermDebtGrossAndLeaseObligation
69246000000 USD
CY2020Q3 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
245000000 USD
CY2019Q3 us-gaap Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost
GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
-76000000 USD
CY2019Q3 cvs Debt Extinguishment Fees
DebtExtinguishmentFees
8000000 USD
CY2019Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
262000000 USD
CY2020Q3 cvs Debt Instrument Unamortized Discountand Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet
971000000 USD
CY2019Q4 cvs Debt Instrument Unamortized Discountand Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountandDebtIssuanceCostsNet
1028000000 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
66995000000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
68480000000 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
5443000000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
3781000000 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
61552000000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
64699000000 USD
CY2020Q3 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
3970000000 USD
CY2020Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
3950000000 USD
CY2020Q1 us-gaap Payments For Proceeds From Derivative Instrument Financing Activities
PaymentsForProceedsFromDerivativeInstrumentFinancingActivities
7000000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-5000000 USD
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost
GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
-706000000 USD
CY2020Q3 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
47000000 USD
CY2020Q3 cvs Debt Extinguishment Fees
DebtExtinguishmentFees
13000000 USD
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-766000000 USD
CY2019Q3 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
5000000 USD
CY2019Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-79000000 USD
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2019Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
CY2020Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.50
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
1.50
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
266000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
236000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
848000000 USD
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16000000 shares
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19000000 shares
CY2020Q3 us-gaap Profit Loss
ProfitLoss
1219000000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
1529000000 USD
us-gaap Profit Loss
ProfitLoss
6217000000 USD
us-gaap Profit Loss
ProfitLoss
4887000000 USD
CY2020Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 USD
CY2019Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
0 USD
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
3000000 USD
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5000000 USD
CY2019Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1224000000 USD
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1530000000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6206000000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4884000000 USD
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1310000000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1302000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1308000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1300000000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
5000000 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3000000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
6000000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3000000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1315000000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1305000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1314000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1303000000 shares
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.93
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.76
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.93
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.75
CY2020Q3 cvs Guarantor Obligations Numberof Leases
GuarantorObligationsNumberofLeases
76 store
CY2013Q1 cvs Loss Contingency Audit Methodology Sample Size
LossContingencyAuditMethodologySampleSize
200 member
us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
6 claim
us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
6 claim
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 Segment
CY2020Q3 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
66852000000 USD
CY2020Q3 us-gaap Net Investment Income
NetInvestmentIncome
204000000 USD
CY2020Q3 us-gaap Revenues
Revenues
67056000000 USD
CY2020Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
3622000000 USD
CY2019Q3 cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
64547000000 USD
CY2019Q3 us-gaap Net Investment Income
NetInvestmentIncome
263000000 USD
CY2019Q3 us-gaap Revenues
Revenues
64810000000 USD
CY2019Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
3947000000 USD
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
198602000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
550000000 USD
us-gaap Revenues
Revenues
199152000000 USD
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13063000000 USD
cvs Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax
PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax
189082000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
805000000 USD
us-gaap Revenues
Revenues
189887000000 USD
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
11573000000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3249000000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2928000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
11387000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
8950000000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
587000000 USD
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
607000000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1751000000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1822000000 USD
CY2020Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
57000000 USD
CY2019Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
111000000 USD
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
196000000 USD
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
365000000 USD
CY2020Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
271000000 USD
CY2019Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-205000000 USD
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
271000000 USD
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-205000000 USD
CY2020Q3 cvs Store Rationalization Charges
StoreRationalizationCharges
0 USD
CY2019Q3 cvs Store Rationalization Charges
StoreRationalizationCharges
96000000 USD
cvs Store Rationalization Charges
StoreRationalizationCharges
0 USD
cvs Store Rationalization Charges
StoreRationalizationCharges
231000000 USD
CY2020Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
3622000000 USD
CY2019Q3 cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
3947000000 USD
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
13063000000 USD
cvs Adjusted Operating Income Loss
AdjustedOperatingIncomeLoss
11573000000 USD

Files In Submission

Name View Source Status
0000064803-20-000041-index-headers.html Edgar Link pending
0000064803-20-000041-index.html Edgar Link pending
0000064803-20-000041.txt Edgar Link pending
0000064803-20-000041-xbrl.zip Edgar Link pending
a09302020ex101.htm Edgar Link pending
a09302020ex151.htm Edgar Link pending
a09302020ex311.htm Edgar Link pending
a09302020ex312.htm Edgar Link pending
a09302020ex321.htm Edgar Link pending
a09302020ex322.htm Edgar Link pending
cvs-20200930.htm Edgar Link pending
cvs-20200930.xsd Edgar Link pending
cvs-20200930_cal.xml Edgar Link unprocessable
cvs-20200930_def.xml Edgar Link unprocessable
cvs-20200930_g1.jpg Edgar Link pending
cvs-20200930_htm.xml Edgar Link completed
cvs-20200930_lab.xml Edgar Link unprocessable
cvs-20200930_pre.xml Edgar Link unprocessable
cvshealtha381.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending